Research Output
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents
  Frequent oncogenic mutations have been identified in MAPK (mitogen-activated protein kinase) signaling pathway components. As a result, MAPK pathway is associated with human cancer initiation, in particular RAF (rapidly accelerated fibrosarcoma) component. The mutation in RAF component leads to auto-activation of MAPK signaling pathway, stimulating the uncontrolled cell growth and proliferation. In last few years, diverse chemical scaffolds have been identified as RAF inhibitors. Most of these scaffolds show potent anti-cancer activity. The present review highlights the recent investigations of RAF inhibitors during the last five years.

  • Type:

    Review

  • Date:

    06 September 2018

  • Publication Status:

    Published

  • Publisher

    Elsevier BV

  • DOI:

    10.1016/j.ejmech.2018.09.005

  • Cross Ref:

    10.1016/j.ejmech.2018.09.005

  • ISSN:

    0223-5234

  • Funders:

    Historic Funder (pre-Worktribe)

Citation

Ammar, U. M., Abdel-Maksoud, M. S., & Oh, C. (2018). Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry, 158, 144-166. https://doi.org/10.1016/j.ejmech.2018.09.005

Authors

Keywords

MAPK, RAF inhibitors, Anti-cancer agents

Monthly Views:

Available Documents